Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations

EP: 1.Myelofibrosis: Characteristics and Subtypes

EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis

EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life

EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals

EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management

EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis

EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison

Now Viewing

EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations

EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies

This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.

Gerds clarifies that JAK inhibitors are not contraindicated in anemic patients, highlighting historical usage with ruxolitinib. He emphasizes the challenges of dose reduction, the potential impact on treatment outcomes, and the need for more thoughtful selection among the available JAK inhibitors. Gerds discusses response monitoring, underlining the significance of patient-reported outcomes, especially the patient's global impression of change. He recommends focusing on symptom improvement and palpable spleen length reduction, simplifying evaluation without the need for advanced imaging. The discussion delves into considerations for altering therapy in myelofibrosis, emphasizing the importance of timely assessment, typically within 3 to 6 months. Gerds discusses the RR6 prognostic model (response to ruxolitinib after 6 months), suggesting key questions at these intervals to guide treatment decisions. This segment provides practical insights for clinicians to navigate the nuanced aspects of JAK inhibitor therapy in myelofibrosis.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.